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Abstract 
Peroxiredoxin-5 (PRDX5) is a thioredoxin peroxidase which reduces hydrogen peroxide, 
alkyl hydroperoxides and peroxynitrite. This enzyme is present in the cytosol, mitochondria, 
peroxisomes and the nucleus in human cells. Antioxidant cytoprotective functions have been 
previously documented for cytosolic, mitochondrial and nuclear mammalian PRDX5. 
However, the exact function of PRDX5 in peroxisomes is still not clear. The aim of this 
work was to determine the function of peroxisomal PRDX5 in mammalian cells, and more 
specifically in glial cells. In order to study the role of PRDX5 in peroxisomes, the 
endogenous expression of PRDX5 in murine oligodendrocyte 158N cells was silenced by 
RNA interference. In addition, human PRDX5 was also overexpressed in peroxisomes using 
a vector coding for human PRDX5 whose unconventional peroxisomal targeting sequence 1 
(PTS1; SQL) was replaced by the prototypical PTS1 SKL. Stable 158N clones were 
obtained. Antioxidant cytoprotective function of peroxisomal PRDX5 against peroxisomal 
and mitochondrial KillerRed-mediated ROS production as well as H2O2 was examined using 
MTT viability assays, roGFP2 and C11-BOBIPY probes. Altogether our results show that 
peroxisomal PRDX5 protects 158N oligodendrocytes against peroxisomal and mitochondrial 
KillerRed- and H2O2-induced oxidative stress. 
Keywords 
Peroxiredoxin-5; peroxisomes; mitochondria; oxidative stress; KillerRed; lipid peroxidation; 
roGFP2. 
Abbreviations  
3-AT, 3-amino-1,2,4-triazole; ATPB, mitochondrial ATP synthase; COX4, cytochrome C 
oxidase subunit 4; E, postnuclear supernatant; GSTK1, glutathione S-transferase Kappa 1; 
Hsp90, heat shock protein 90; KR, KillerRed; L, light mitochondrial fraction; L-PRDX5, 
long form of peroxiredoxin-5; M, mitochondrial fraction; mt-KR, mitochondrial KillerRed; 
N, nuclear fraction; NEM, N-ethyl-maleimide; po-KR, peroxisomal KillerRed; PRDX5, 
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peroxiredoxin-5; PTS1, peroxisomal targeting sequence 1; ROS, reactive oxygen species; 
SOD1, superoxide dismutase 1; SP, remaining supernatant; S-PRDX5, short form of 
peroxiredoxin-5; TRX1, thioredoxin-1; TRX2, thioredoxin-2; X-ALD, X-linked  
adrenoleukodystrophy 
 
Introduction 
Peroxisomes are essential organelles which participate in multiple important metabolic 
processes, including the -oxidation of fatty acids, plasmalogen synthesis and the 
metabolism of reactive oxygen species (ROS) [1]. Their essential roles are emphasized in 
various genetic diseases such as Zellweger syndrome and X-linked adrenoleukodystrophy 
(X-ALD), in which the integrity of the organelle is compromised [2]. In addition, mice 
lacking peroxisomes specifically in oligodendrocytes develop physiopathological conditions 
similar to X-ALD, including demyelination and axonal damage [3]. Peroxisomes produce 
ROS (hydrogen peroxide and superoxide radical) as part of their normal oxidative functions 
(e.g the -oxidation of a variety of fatty acids and fatty acid derivatives, the degradation of 
D-amino acids) [4]. Peroxisomal ROS have been suggested to be implicated in aging [5-6], 
redox signaling [7-8], and the pathogenesis of several age-related and neurodegenerative 
disorders [9]. Peroxisomes also contain a variety of non-enzymatic (e.g. glutathione) and 
enzymatic antioxidants (e.g. catalase, superoxide dismutase 1 (SOD1), and glutathione S-
transferase kappa 1 (GSTK1)) involved in the degradation of ROS. Several studies have 
demonstrated the role of catalase [10-13], SOD1 [8], and GSTK1 [8] in the antioxidant 
defense of peroxisomes. However, the role of mammalian peroxisomal PRDX5 as 
antioxidant cytoprotective enzyme remained to be established. 
PRDX5 is a thioredoxin reductase which reduces H2O2, alkyl hydroperoxides and 
peroxynitrite [14]. PRDX5 is an atypical 2-Cys PRDX. Its catalytic mechanism leads to the 
formation of an intramolecular disulfide bridge unlike other PRDXs that form an 
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intermolecular disulfide bridge between two monomers (for review see 14). Reduction of the 
oxidized PRDX5 is mediated by thioredoxin-1 (TRX1) in the cytosol and the nucleus, and 
thioredoxin-2 (TRX2) in mitochondria [14]. Among the six members of the mammalian 
PRDX family, PRDX5 presents the widest subcellular distribution. Indeed, two alternative 
translation initiation sites lead to two forms of PRDX5: a long form (L-PRDX5) which is 
addressed to mitochondria, and a short form (S-PRDX5) which is located in the cytosol, the 
nucleus and peroxisomes [15-16]. The peroxisomal localization of S-PRDX5 is due to the 
presence of a C-terminal peroxisomal targeting sequence (PTS1; SQL) [17]. Our group and 
others have highlighted the specific roles of PRDX5 in different subcellular compartments in 
which the enzyme is present. Overexpressing S-PRDX5 and L-PRDX5 have been shown to 
protect Chinese hamster ovary cells against extracellular peroxides [18-19]. Overexpression 
of L-PRDX5 reduces hypoxia-mediated mitochondrial ROS [20], prevents MPP+-mediated 
apoptosis and could affect redox modulation of Ca2+ transport by a possible ER-
mitochondria crosstalk in SH-SY5Y neuroblastoma cells [21]. In addition, silencing of 
PRDX5 in these cells resulted in an increase of MPP+-mediated apoptosis [22]. Interestingly, 
it must be noted that PMP20, the yeast ortholog of PRDX5 in Candida boidinii and 
Hansenula polymorpha, is exclusively located in peroxisomes and has been found to be an 
essential antioxidant enzyme that exhibits a cytoprotective effect [23-25]. 
In this study, we selected 158N oligodendrocyte clones stably transfected to express different 
levels of PRDX5 in order to investigate the potential cytoprotective antioxidant role of 
peroxisomal PRDX5. Here, we report that the peroxisomal form of PRDX5 exerts a 
cytoprotective function against oxidative attacks induced by exogenous H2O2 and 
photoactivated peroxisomal as well as mitochondrial KillerRed. 
Materials and Methods 
DNA manipulations and plasmids 
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The plasmids encoding po-KR and mt-roGFP2 have been described elsewhere [7]. The 
mammalian expression vectors pKillerRed-dmito (Bio-Connect), pcDNA3.1, pCR2.1 TOPO 
(Invitrogen), pSILENCER3.1-H1 puro and pSILENCER3.1-H1 puro Negative control (here 
named p-sh-scrambledRNA) (Ambion) were commercially obtained. The pcDNA3.1 
plasmid encoding po-Grx1-roGFP2 was constructed as follows: (i) the cDNA encoding po-
Grx1-roGFP2 was amplified by PCR (template: pLPCX-GRX1-roGFP2-SKL [26] kindly 
provided by Prof. Andreas Meyer, INRES, University of Bonn, Germany; primers: BamHI-
Grx1-roGFP2 5’-gacaggatccaccatggctcaagagtttgtg-3’ (forward) and Grx1roGFP2-Sal1 5’-
attttgtcgacttaaagcttagacttg-3’(reverse)) and subcloned into PCR2.1-TOPO; (ii) the resulting 
plasmid was digested by SalI/BamHI and the insert was subcloned into pcDNA3.1 to 
generate the plasmid p-poGrx1-roGFP2. The plasmid encoding human po-PRDX5 was 
generated as follows: (i) the cDNA encoding human S-PRDX5 was amplified by PCR 
(template: PCR2.1-PRDX5; primers: PRDX5-Hs-SKL-NotI 5’-
ggcgcggccgctcagagctttgagatgatattgg-3’ (forward) and PRDX5-Cf-SpeI 5’-
agcgactagtccgccatggccccaatcaaggtgggagatgc-3’ (reverse)) and subcloned into PCR2.1-
TOPO; (ii) the resulting plasmid was digested with NotI/SpeI to obtain the human po-
PRDX5 sequence, which was subsequently ligated into the pEF-BOS vector [18 , 27] to 
generate the plasmid p-poPRDX5. The plasmid p-poPRDX5-C47S was constructed the same 
way but pRE30-PRDX5-C47S was used as template. Mammalian vector pSILENCER 
(Ambion) was used to silence murine PRDX5 expression. The shRNAs were designed 
according to ‘siRNA Target Finder’ at the Ambion website 
(http://www.ambion.com/techlib/misc/siRNA_finder.html). The construction of the pSIl-
siPRDX5 plasmid used for expressing siRNAs was performed as described previously [22]. 
The target sequence to silence murine PRDX5 expression was 5’-aaagaagcaggttgggagtgt-3’. 
All the constructs were verified by sequencing. 
Cell culture, C11-BODIPY, transfection and immunofluorescence microscopy  
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The murine oligodendrocyte 158N cell line [28], which was provided by Prof. Said 
Ghandour (University of Strasbourg, France), was cultured in DMEM 4.5 g d-glucose/L with 
GlutaMAX, supplemented with 10% FCS. The cell line was maintained at 37 °C in 5% CO2 
in the presence of 100 U/ml streptomycin and 100 U/ml penicillin. Cells were transfected 
using a Nucleofector instrument according to manufacturer’s instructions (Amaxa 
Biosystems). Immunostaining was performed as described previously [15], using 1:200 
mouse anti-mitochondrial ATP synthase (ATPB; Abcam), 1:100 sheep anti-catalase 
(Biodesign) (Figs. 3 and 7C), 1:50 goat polyclonal anti-catalase (GeneTex) (Figs. 1A, 5A 
and 5B), 1:200 rabbit anti-PRDX5 [29], or 1:50 mouse monoclonal anti-human PRDX5 (286 
6F7; Millipore). C11-BODIPY 581/591 (Molecular Probes) at 1 µM was incubated with 
growth medium without red phenol for 30 min at 37°C, then the free thiols were clamped 
with 10 mM of N-ethyl-maleimide (NEM) (Sigma) for 10 min at 37°C. Finally, the cells 
were fixed in 4% paraformaldehyde before mounting and imaging. Confocal images were 
acquired with a Zeiss 710 confocal microscope (Carl Zeiss) which was equipped with Plan-
Apochromat 63x/1.40 NA objective (oil immersion). RoGFP2 is a mutated enhanced green 
fluorescent protein with two cysteine residues exposed at the outer surface of the -barrel 
which forms a disulfide bond in oxidizing conditions [30-31]. The formation of this disulfide 
bond changes the excitation wavelength of the roGFP2 [31]. Thus, the roGFP2 presents two 
excitation wavelengths (i) at  490 nm when the roGFP2 is reduced and (ii) at  400 nm when 
the roGFP2 is oxidized [31]. The ratio of the two roGFP2 emissions (at  510nm) allows the 
monitoring of the redox status of the surrounding environment [30-31]. Measurements of 
roGFP2 redox status were performed on a motorized IX-81 microscope equipped with a 
temperature, humidity, and CO2-controlled incubation chamber and analyzed as described 
elsewhere [7]. 
Subcellular fractionation 
15x106 158N cells were homogenized in 250 µl of homogenization solution at pH 7.2 (250 
mM sucrose, 5 mM Mops, 1 mM EDTA, 0,1% ethanol, 1 mM DTT) by three strokes of 
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Potter-Elvehjem homogenizer. Briefly, the homogenate was centrifuged at 500 g for 10 min 
to pellet the nuclear fraction (N). The postnuclear supernatant (E) was centrifuged at 2330 g 
for 10 min to pellet the heavy mitochondrial fraction (M). The resulting supernatant was 
centrifuged at 13000 g for 20 min to pellet the light mitochondrial fraction (L). The 
remaining supernatant (SP) and the M fraction were centrifuged at 20000 g for 60 min 
through a self-generating Percoll gradient (40% Percoll (w/v), 220 mM sucrose, 1 mM 
Mops, 0.1% ethanol, 1 mM DTT, pH 7.2). Equal volume fractions were collected from the 
bottom of the tube with a peristaltic pump.  
Generation of stable 158N clones expressing different levels of PRDX5 
158N cells were transfected with combination of plasmids using a Nucleofector instrument 
according to manufacturer’s instructions (Amaxa Biosystems). Three days after transfection, 
cells were exposed to 4 µg/ml puromycin for selection. Subsequently, stably transfected cell 
clones were obtained by isolation of individual clones by dilution. PRDX5 expression was 
analyzed by immunofluorescence and Western blotting (see Figs. 2, 3 and 7A-C). 
Incorporation of replication arrest sequence from pEF-BOS vector in the genome of control 
and shPRDX5 cells was verified by PCR on genomic DNA using the primers: terpef-f 5’-
gcatccccttggctgtgaggcc-3’ (forward) and terpef-r 5’-caggagacgcgtcggtgatgttcggg-3’ (reverse) 
(data not shown). Incorporation of sh scrambled-RNA sequence from p-scrambled-sh-RNA 
in the genome of control and po-PRDX5 high cells was verified by PCR on genomic DNA 
using the primers: f-pSIL 5’-gcgattaagttgggtaacgc-3’ (forward) and r-pSIL 5’-
cacaggaaacagctatgacc-3’ (reverse) (data not shown). Genomic DNA was extracted from 
5x106 cells using DNeasy Blood and Tissue kit (Qiagen) following manufacturer’s 
instructions. 
Western blotting  
Western blotting was performed as described previously [18] with the following diluted 
antibodies: 1:5000 mouse monoclonal anti-catalase (CAT-505; Sigma), 1:2000 mouse 
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monoclonal anti-cytochrome c oxidase subunit 4 (COX4; Molecular Probes), 1:1000 mouse 
monoclonal anti-heat shock protein 90 (Hsp90; Millipore), 1:5000 rabbit polyclonal anti-
PRDX3 [22], 1:5000 rabbit polyclonal anti-PRDX5 [29], 1:200 mouse monoclonal anti-
human PRDX5 (286 6F7; Millipore), 1:2000 rabbit polyclonal anti-actin (Sigma), and 
chemiluminescence ECL Western blotting detection was performed as previously described 
[18]. 
Light irradiation and cell viability assays  
For the cell viability, lipid peroxidation, and Western blotting assays, the cells were seeded 
in 96- or 24-well cell culture plates or 35 mm tissue culture dishes (Falcon), respectively, 
and irradiated with green light (irradiance  15 mW/cm2) using a KL1500LCD cold light 
source with a green insert filter (P/N 158 304; Schott). Light dose (J/cm2) was calculated by 
multiplying the irradiance (W/cm2) by the exposure time (s). MTT cell viability assays were 
performed as described elsewhere [8]. 
Statistical analysis  
Statistics were performed using JMP 9.0 software (SAS). ANOVA2 with Tukey ‘s post-hoc 
test was chosen to determine statistical differences for MTT assays and roGFP2 
measurements. 
Results 
Peroxisomal PRDX5 expression in murine oligodendrocyte 158N cell line  
The murine oligodendrocyte 158N cell line was used as previous studies showed that 
peroxisomes are present in these cells and are involved in myelin metabolism [32]. We first 
examined the subcellular PRDX5 localization using immunofluorescence. PRDX5 was 
localized in peroxisomes by catalase codetection (Fig. 1A) and in mitochondria by 
colocalization with mitochondrial membrane ATP synthase (ATPB) (Fig. 1B). To confirm 
immunofluorescence localization of PRDX5 in peroxisomes and mitochondria, PRDX5 
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localozation was also examined using subcellular fractionation on Percoll gradient. Equal 
volume fractions were analyzed by Western blotting. Our data show that PRDX5 is present 
in fractions enriched with COX4 (mitochondrial marker), catalase (peroxisomal marker) and 
Hsp90 (cytosolic marker) (Figs. 1C and 1D). These two experiments showed that the 
peroxisomal form of PRDX5 is indeed expressed in the 158N cell line. 
Selection of 158N clones expressing PRDX5 in peroxisomes 
Two mammalian expression vectors were used to modulate the expression of PRDX5 in 
peroxisomes. The first vector is a pSILENCER vector (p-shPRDX5) coding for a RNA 
hairpin targeted to mRNA coding for murine PRDX5. This vector was used to silence 
endogenous murine PRDX5 expression. The second vector is a pEF-BOS vector coding for a 
human S-PRDX5 variant in which the unconventional peroxisomal targeting sequence 1 
(PTS1) SQL was replaced by the prototypical PTS1 SKL (p-po-PRDX5) to force the cell to 
address PRDX5 to peroxisomes. The RNA hairpin targeted to the murine PRDX5 mRNA 
did not recognize the human PRDX5 mRNA. Indeed, human neuroblastoma SH-SY5Y cells 
transfected with p-shPRDX5 did not show a decrease of PRDX5 expression after puromycin 
selection (data not shown). These two vectors and their respective control (p-sh-scrambled 
and pEF-BOS-empty) were transfected to select clones. 
After transfection of 158N cells with various combinations of control vectors (p-sh-
scrambled and pEF-BOS-empty), p-shPRDX5 and p-po-PRDX5, stable clones were 
selected. The stable clones were named control (p-sh-scrambled and pEF-BOS-empty), 
shPRDX5 (p-shPRDX5 and pEF-BOS-empty), po-PRDX5 high (p-sh-scrambled and p-po-
PRDX5), or shPRDX5/po-PRDX5 (p-shPRDX5 and p-po-PRDX5). Expression levels of 
PRDX5 in these clones were analyzed by immunofluorescence (Fig. 2A) and 
immunoblotting (Fig. 2B) using a polyclonal antibody recognizing human and murine 
PRDX5. In the shPRDX5 clone, lower PRDX5 expression was observed compared to 
control clone by immunofluorescence (Fig. 2A) and was 2-fold lower as measured by 
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Western blotting (Fig. 2B and 2C). The po-PRDX5 high clone presented a 3.2-fold 
overexpression compared to the control clone (Fig. 2B and 2C). PRDX5 expression in po-
PRDX5 high clone was mainly localized in peroxisomes but some PRDX5 was not properly 
targeted and remained in the cytosol (Fig. 2A). Immunofluorescence showed that in the 
shPRDX5/poPRDX5 clone, a punctuated distribution of PRDX5 was present, which is 
typical of a peroxisomal localization (Fig. 2A). Immunoblotting revealed a 0.3-fold lower 
expression of shPRDX5 clone compared to the control clone (Fig. 2B and 2C). Note that 
shPRDX5/poPRDX5 clones were selected in order to keep a PRDX5 expression level 
similar to control clones. Peroxisomal expression of human S-PRDX5 was assessed by 
immunofluorescence using a specific monoclonal antibody recognizing human PRDX5 but 
not murine PRDX5 and a specific antibody targeted against catalase (peroxisomal marker). 
In po-PRDX5 high and shPRDX5/po-PRDX5 clones, human PRDX5 was largely located in 
peroxisomes (Fig. 3C and 3D, respectively). 
Resistance and sensitivity of 158N clones to oxidative stress 
To investigate the antioxidant protection of peroxisomal PRDX5, 158N clones with different 
expression levels and subcellular localizations of PRDX5 were exposed to several kinds of 
acute oxidative stress, including increasing concentrations of H2O2 or tBHP. Cell death, 
assessed with MTT assay, was significantly higher in control and shPRDX5 cells compared 
to po-PRDX5 and shPRDX5/po-PRDX5 cells exposed to 100 µM H2O2 (Fig. 4). At 250 µM 
H2O2, no significant difference was observed. At the same concentrations of tBHP, no 
significant difference was observed and cell death was above 70% in each condition (data 
not shown). 
To gain insight into the antioxidant protection of peroxisomal PRDX5 against ROS 
production in peroxisomes and mitochondria, we triggered targeted oxidative stress using 
KillerRed (KR) [7]. KR is a photosensitizer developed from a mutated red fluorescent 
protein which generates ROS upon green light illumination [33]. KR has been reported to 
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produce superoxide, singlet oxygen and hydrogen peroxide [33-34]. However, recent studies 
demonstrate that the major ROS formed by KR is superoxide [35-36]. We employed 
peroxisomal and mitochondrial targeted variants of KR [7] to generate oxidative stress in 
these compartments. We first verified peroxisomal and mitochondrial localizations of po-KR 
and mt-KR in 158N cells with specific markers (Figs. 5A and 5B, respectively). Po-KR and 
mt-KR showed colocalization with catalase and ATPB, respectively. Levels of cell death 
induced by the phototoxicity of peroxisomal KillerRed (po-KR) and mitochondrial KillerRed 
(mt-KR) were similar for the control clone (Figs. 6A and 6B, respectively). Cell death of the 
shPRDX5 clone was statistically higher than that of control clone in po-KR-induced stress 
(Fig. 6A). Moreover, the clones overexpressing peroxisomal PRDX5 showed a marked 
reduction of cell death compared to the control clone after KR-induced stress (Figs. 6A and 
6B). Taken together, these results suggest that, in peroxisomes, PRDX5 exerts an antioxidant 
protection. 
Is cell death decrease in overexpressing peroxisomal PRDX5 clones exposed to oxidative 
stress linked to PRDX5 peroxidatic activity? 
Since addressing human PRDX5 to peroxisomes increased cell viability against KR-induced 
ROS generation both in peroxisomes and mitochondria, we examined whether this 
cytoprotection was dependent on PRDX5 peroxidatic activity. We selected 158N clones 
overexpressing peroxisomal PRDX5-C47S, a PRDX5 mutant which lacks peroxidatic 
activity [37]. Po-PRDX5-C47S and shPRDX5/po-PRDX5-C47S clones were generated 
(Figs. 7 A, B and C), both expressing the enzymatically inactive human peroxisomal S-
PRDX5 with the C47S and SKL mutations, and respectively expressing either shscrambled 
RNA or shPRDX5 RNA. The relative expression of the mutant PRDX5 was assessed by 
immunofluorescence (Fig. 7A) and quantified by Western blotting (Fig. 7B). Immunoblots 
revealed a 3-fold and a 2.3-fold higher PRDX5 expression for respectively the po-PRDX5-
C47S and the shPRDX5/po-PRDX5-C47S clones (Fig. 7B). In po-PRDX5-C47S and 
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shPRDX5/po-PRDX5-C47S clones, human PRDX5 was found to colocalize with catalase as 
expected (Fig. 7C). 
The PRDX5-C47S clones were exposed to oxidative stress induced by po-KR and mt-KR 
and found to be as vulnerable to KR-induced oxidative stress as the control clone (Fig. 7D 
and 7E, respectively). However, note that the po-PRDX5-C47S clone after po-KR activation 
showed no significant difference compared to non-illuminated cells (Fig. 7D). These results 
showed that the peroxidatic activity should be partly responsible for the cytoprotection of 
peroxisomal PRDX5. However, other factors not yet identified could be involved in this 
protection. 
Overexpressing peroxisomal PRDX5 prevents lipid peroxidation induced by po-KR  
As it was reported that po-KR and mt-KR induce oxidative stress and generate lipid 
peroxidation, and that this effect can be counteracted by overexpressing antioxidant enzymes 
[8], we examined whether the peroxisomal PRDX5 could also protect against po-KR- and 
mt-KR-induced lipid peroxidation. Therefore, we used the lipid peroxidation sensor C11-
BODIPY 581/591. C11-BODIPY 581/591 is a fluorescent fatty acid analogue which has a 
comparable sensitivity to oxidation to that of endogenous fatty acyl moieties [38]. Upon 
peroxidation, the red fluorescence of this sensor shifts to green fluorescence. As this probe 
and KR display overlapping red fluorescence, the visualization of the lipid peroxidation was 
only detected in the green channel [8]. Control and shPRDX5 clones displayed an increase in 
green channel imaging after illumination for both po-KR and mt-KR (Figs. 8 and 9, 
respectively). The percentage of green positive cells (  10%) was comparable for both po-KR 
and mt-KR. However, the clones overexpressing peroxisomal PRDX5 (po-PRDX5 high and 
shPRDX5/po-PRDX5) did not show an increase in the green channel imaging (Figs. 8 and 
9).  
Effects of catalase inhibition on peroxisomal and mitochondrial redox balance  
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To highlight the role of peroxisomal PRDX5 in the balance of intracellular redox status, we 
used targeted variants of roGFP2 and we treated 158N clones, presenting different levels of 
PRDX5 expression, with a catalase inhibitor (3-amino-1,2,4-triazole (3-AT)) [7]. 
Peroxisomal and mitochondrial redox status were assayed after transfection of the 158N 
clones with vectors expressing po-Grx1-roGFP2 and mt-roGFP2 [7 , 26]. The correct 
localization of po-Grx1-roGFP2 and mt-roGFP2 in 158N cells was verified by 
immunofluorescence with peroxisomal and mitochondrial markers (catalase and ATPB 
respectively) (Figs. 5A and 5B, respectively). Compared to the control clone in basal 
conditions, the peroxisomal redox status of the shPRDX5 and shPRDX5/poPRDX5 clone 
was slightly but significantly higher. Surprisingly, in non treated conditions, the peroxisomal 
redox status of the po-PRDX5 high was significantly higher (Fig. 10A). Catalase inhibition 
by 3-AT resulted in a slight but significant decrease of the peroxisomal redox status of the 
control, shPRDX5 and po-PRDX5 high clones (Fig. 10A). In basal conditions, the 
mitochondrial redox status of overexpressing peroxisomal PRDX5 clones (po-PRDX5 high 
and shPRDX5/po-PRDX5) were slightly but significantly higher than the control clone (Fig. 
10B). As previously observed with wild-type MEFs [7], catalase inhibition in the control and 
the shPRDX5 clones resulted in a slight but significantly increase of the mitochondrial redox 
status. Remarkably, in clones overexpressing peroxisomal PRDX5, treatment with 3-AT did 
not result in an increase of the mitochondrial redox status. 
Discussion 
Recent studies demonstrated that peroxisomal ROS can lead to cell death and may be also 
involved in a complex interorganellar crosstalk [7-8 , 13]. Moreover, the relative importance 
of several antioxidant enzymes in the reduction of these peroxisomal ROS was underlined [8 
, 13]. In this context, we examined the antioxidant role of PRDX5 in peroxisomes.  
Here, we show that PRDX5 is indeed localized in peroxisomes of the mouse oligodendrocyte 
158N cell line. Subsequently, using different constructs, we selected stable clones with 
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different levels of human PRDX5 expression. Our results show that overexpression of 
peroxisomal PRDX5 exerts a cytoprotective role against oxidants such as exogenously 
applied H2O2.  
We extended our observations on peroxisomal PRDX5 by using cell model assays based on 
the phototoxicity of KR [8]. This cell model allowed us to trigger localized oxidative stress 
in peroxisomes and mitochondria. Our results show that global silencing of PRDX5 
sensitizes the cells to po-KR and mt-KR phototoxicity. Furthermore, overexpression of the 
peroxisomal PRDX5 protected against po-KR and mt-KR derived ROS. Moreover, 
overexpression of PRDX5 in peroxisomes preserved from lipid peroxidation induced by KR-
derived ROS. PRDX5 could probably act in concert with GSTK1 in peroxisomes to detoxify 
lipid peroxides. GSTK1 has a peroxidase activity [39] and GSTK1 overexpression was 
shown also to protect against lipid peroxidation induced by po-KR- and mt-KR-induced 
stress [8]. Here, it must be pointed out that PRDX5 is more efficient to reduce organic 
peroxides and peroxynitrite (rate constant in the 106-107 M-1 s-1 range) compared to H2O2 
(rate constant of 3 ± 0.5x105 M-1 s-1) [40]. Interestingly, catalase overexpression did not act 
as a lipid peroxidation quencher following po-KR- and mt-KR-induced stress [8]. These data 
suggest that PRDX5 could act both by preventing lipid peroxidation by previous 
decomposition of peroxides (with a higher affinity for peroxynitrite) or by direct lipid 
peroxide reduction. Two other peroxidases which reduce lipid peroxides in the cytosol and 
the membranes are PRDX6 [41] [42] and GPx4 [43] [44] [45]. Notably, GPx4 was shown 
also to protect mitochondria from lipid peroxidation [46]. Thus, GSTK1, PRDX5, PRDX6 
and GPx4 could act with their specific subcellular localization to control lipid peroxidation 
and/or subsequent redox cell signaling.  
Here, we report also that a peroxisomal PRDX5 mutant that does not display peroxidatic 
activity did not protect from phototoxicity induced by po-KR and mt-KR for the 
shPRDX5/po-PRDX5-C47S clone. However, cells from the po-PRDX5-C47S clone were 
protected from mt-KR-induced phototoxicity. These results suggest that the cytoprotective 
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effect of the PRDX5 is partially linked to its peroxidatic activity. The cytoprotection 
observed in the po-PRDX5-C47S could be due to compensation by other peroxisomal 
antioxidant enzymes. In this context, we showed that liver cells from pig, in which the L-
PRDX5 targeting was lost during evolution, express more PRDX3 and GPX4 than rat liver 
cells [47].  
Our observations also strengthen the concept of a redox cross-talk between peroxisomes and 
mitochondria [7]. Indeed, overexpression of peroxisomal PRDX5 protected from a 
mitochondrial oxidative stress induced by KR. In addition, we confirmed that inhibiting 
catalase by 3-AT disturbs the mitochondrial redox status but overexpressing peroxisomal 
PRDX5 counteracts this effect.  
Surprisingly, inhibiting catalase by 3-AT led to a decrease or maintained the peroxisomal 
redox status for all clones. Previous studies have shown that inhibition of catalase by 3-AT 
of mouse embryonic fibroblasts (MEF) or catalase deficient-MEF maintain their peroxisomal 
redox status while their mitochondrial redox status is increased [7]. In addition, inhibiting 
catalase of human fibroblats by 3-AT led to activity inhibition of mitochondrial aconitase 
[48] and chronic treatment by 3-AT resulted in proliferation of peroxisomes [12]. Moreover, 
catalase deficient-yeast Hansenula polymorpha cells showed different chronological life 
spans (CLS) upon growth conditions [49]. Several hypotheses can be ruled out to explain 
those responses. First, absence or decrease of catalase could increase the activity or the 
import of other peroxisomal antioxidant enzymes, which in turn would induce the decrease 
or maintain of the peroxisomal redox status. Second, a crosstalk from peroxisomes to 
mitochondria in which H2O2 or peroxisomal lipid metabolites are involved, could induce 
mitochondrial redox status increase. However, 3-AT could either lead to a yet unknown 
inhibition of a mitochondrial antioxidant enzyme or perturb the mitochondrial electron 
transport chain leading to an increase of mitochondrial redox status.  
16 
 
In conclusion, our results showed that peroxisomal PRDX5 exerts an antioxidant protection, 
and that PRDX5 protects from lipid peroxidation induced by KR-phototoxicity. However, 
the relative role of PRDX5 compared to other antioxidant enzymes in peroxisomes remains 
to be elucidated.  
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Figure legends 
Figure 1. Subcellular localization of PRDX5 in 158N cell line. Immunostaining of PRDX5 
and colocalization with (A) catalase (peroxisomal marker) and (B) ATPB (mitochondrial 
marker). Nuclei were stained with DAPI. Scale bars: 10 µm. (C) Subcellular fractionation on 
Percoll gradient. Nuclear (N), heavy mitochondrial (M) and (D) cytosolic/microsomal 
fractions (SP) were analyzed for PRDX5 and for marker enzyme by Western blotting, 
PRDX5 is present in fractions enriched in COX4 (mitochondrial marker), catalase 
(peroxisomal marker) and Hsp90 (cytosolic marker).  
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Figure 2. Endogenous and peroxisomal human PRDX5 expression in transfected 158N 
clones. Silencing of endogenous PRDX5 expression and overexpression of human 
peroxisomal PRDX5 was examined by (A) immunofluorescence  and (B) Western blotting 
and total expression levels were quantified (C). Bands arise from the same blot but were 
reorganized to respect the disposition of clones on the figure. Scale bars: 10 µm. 
Figure 3. Subcellular localization of human po-PRDX5 in 158N clones. Immunostaining of 
human po-PRDX5 and colocalization with catalase (peroxisomal marker). Scale bars: 10 
µm. 
Figure 4. Viability assays on 158N clones exposed to hydrogen peroxide. Cells were 
exposed to increasing concentrations of hydrogen peroxide (50, 100 and 250 µM) for 24 h, 
and MTT viability assay was performed. n=9 per group, mean values come from three 
independent experiments followed by ANOVA2 statistical analysis. Significance versus 
without treatment: a,b,c,dp<0.05,   aa,bb,cc,ddp<0.01, aaa,bbb,ccc,dddp<0.0001.  
Figure 5. (A) Colocalization by immunofluorescence of po-Grx1-roGFP2 and po-KR with 
catalase (peroxisomal marker. (B) Colocalization by immunofluorescence of mt-roGFP2 and 
mt-KR with ATPB (mitochondrial marker). Nuclei were stained with DAPI. Scale bars: 10 
µm. 
Figure 6. Viability assays on 158N clones. 158N clones were transiently transfected with a 
plasmid encoding peroxisomal (A) or mitochondrial (B) KillerRed, after three (peroxisomal) 
or two (mitochondrial) days, cells were illuminated for 1h (black) or not illuminated (no 
treatment, grey) to green light. 24h post-illumination, MTT assays were performed. n=9 per 
group. Mean values come from three independent experiments followed by ANOVA2 
statistical analysis. Significance versus no treatment is indicated by *p<0.05, **p<0.01, 
***p<0.0001. The values from illuminated control clone condition were also compared to 
the other illuminated conditions ( p<0.05). 
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Figure 7. Subcellular localization and expression of mutant PRDX5-C47S in 158N clones 
and viability assays. (A) Immunostaining of endogenous murine and exogenous human 
PRDX5. (B) Western blotting analysis of PRDX5 mutants and (C) blot quantification. Bands 
arise from the same blot but were reorganized to respect the disposition of clones on the 
figure. Immunostaining of human PRDX5-C47S and colocalization with catalase. 158N 
clones were transiently transfected with a plasmid encoding peroxisomal (D) or 
mitochondrial (E) KillerRed, after three (peroxisomal) or two (mitochondrial) days, cells 
were illuminated for 1h (dark) or not illuminated (no treatment, grey) to green light. 24h 
post-illumination, MTT assays were performed. n=9 per group. Mean values from three 
independent experiments followed by ANOVA2 statistical analysis. Significance versus no 
treatment is indicated by *p<0.05, **p<0.01, ***p<0.0001. The values from illuminated 
control clone were also statistically compared to the other illuminated conditions ( p<0.05).  
 
Figure 8. Sensing of peroxisomal KillerRed-induced lipid peroxidation in 158N clones. 
158N clones were transiently transfected with a plasmid encoding peroxisomal KR (po-KR). 
After three days, cells were illuminated (54 J/cm2) for 1h or not illuminated (0 J/cm2) to 
green light. After illumination, cells were incubated for 30 min at 37°C with BODIPY C11 
(10 µM). Then cells were incubated with NEM (10 mM) for 10 min at 37°C. Finally, the 
cells were fixed in PFA 4% for 30 min at RT and then visualized in fluorescence microscopy 
as described in “Materials and Methods”. Oxidation of BODIPY-C11 results in a shift of the 
emission spectra from red to green. Scale bars: 10 µm. 
Figure 9. Sensing of mitochondrial KillerRed-induced lipid peroxidation in 158N clones. 
158N clones were transiently transfected with a plasmid coding for mitochondrial KR (mt-
KR). After two days, cells were illuminated (54  J/cm2) for 1h or not illuminated (0 J/cm2) to 
green light. After illumination, cells were incubated for 30 min at 37°C with BODIPY C11 
(10 µM). Then cells were incubated with NEM (10 mM) for 10 min at 37°C. Finally, the 
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cells were fixed in PFA 4% for 30 min at RT and then visualized in fluorescence microscopy 
as described in “Materials and Methods”. Oxidation of BODIPY-C11 results in a shift of the 
emission spectra from red to green. Scale bars: 10 µm. 
Figure 10. Intracellular redox status in 158N clones and under catalase inhibition. 158N 
clones were transiently transfected with plasmids encoding for mitochondrial roGFP2 (mt-
roGFP2) or peroxisomal Grx1-roGFP2 (po-Grx1-roGFP2). After three days, the cells were 
exposed to 10 mM of 3-aminotriazole (catalase inhibitor) for 4 hours, then redox status was 
measured in mitochondria (A) or peroxisomes (B). 400/480 nm ratios were analyzed as 
described in [7]. Data were normalized to the control clone non-treated, followed by 
ANOVA2 statistical analysis. Significance versus control is indicated by *p<0.05, **p<0.01, 
***p<0.0001. The values from the non-treated control clone were also statistically compared 
to the other non treated conditions ( p<0.05). 
Walbrecq et al., Antioxidant cytoprotection of peroxisomal peroxiredoxin-5, MS #: 
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Highlights 
 Peroxisomal PRDX5 exerts a cytoprotective function against exogenous H2O2 
 Peroxisomal PRDX5 protects from peroxisomal and mitochondrial KillerRed-
mediated ROS  
 Peroxisomal PRDX5 acts towards lipid peroxidation 
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